A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease

Objectives The association between mutations in TNFAIP3, encoding the NF-kB regulatory protein A20, and a new autoinflammatory disease has recently been recognised. This study aims at describing the clinical phenotypes and disease course of patients with A20 haploinsufficiency (HA20). Methods Data for all cases from the initial publication, and additional cases identified through collaborations since, were collected using standardised data collection forms. Results A total of 16 patients (13 female) from seven families with a genetic diagnosis of HA20 were included. The disease commonly manifested in early childhood (range: first week of life to 29 years of age). The main clinical symptoms were recurrent oral, genital and/or gastrointestinal ulcers (16/16), musculoskeletal (9/16) and gastrointestinal complaints (9/16), cutaneous lesions (8/16), episodic fever (7/16), and recurrent infections (7/16). Clinical phenotypes varied considerably, even within families. Relapsing-remitting disease course was most common, and one patient died. Laboratory abnormalities included elevated acute-phase reactants and fluctuating presence of various autoantibodies such as antinuclear antibodies (4/10 patients tested) and anti-dsDNA (2/5). Tissue biopsy of different sites revealed non-specific chronic inflammation (6/12 patients tested), findings consistent with class V lupus nephritis in one patient, and pustules and normal results in two patients each. All patients were treated: 4/16 received colchicine and 12/16 various immunosuppressive agents. Cytokine inhibitors effectively suppressed systemic inflammation in 7/9 patients. Conclusions Early-onset recurrent oral, genital and/or gastrointestinal ulcers are the hallmark feature of HA20. Frequency and intensity of other clinical manifestations varied highly. Treatment regimens should be based on disease severity, and cytokine inhibitors are often required to control relapses.

[1]  O. Ozcebe,et al.  Behçet's disease. , 2019, The New England journal of medicine.

[2]  M. McDermott,et al.  Faculty Opinions recommendation of Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[3]  J. Coxhead,et al.  Early-onset autoimmune disease due to a heterozygous loss-of-function mutation in TNFAIP3 (A20) , 2017, Annals of the rheumatic diseases.

[4]  S. Miyano,et al.  Haploinsufficiency of TNFAIP3 (A20) by germline mutation is involved in autoimmune lymphoproliferative syndrome , 2017, The Journal of allergy and clinical immunology.

[5]  E. Remmers,et al.  Brief Report: Deficiency of Complement 1r Subcomponent in Early‐Onset Systemic Lupus Erythematosus: The Role of Disease‐Modifying Alleles in a Monogenic Disease , 2017, Arthritis & rheumatology.

[6]  Qing Zhou,et al.  NF-κB Pathway in Autoinflammatory Diseases: Dysregulation of Protein Modifications by Ubiquitin Defines a New Category of Autoinflammatory Diseases , 2017, Front. Immunol..

[7]  Keiko Kobayashi,et al.  Novel heterozygous C243Y A20/TNFAIP3 gene mutation is responsible for chronic inflammation in autosomal-dominant Behçet's disease , 2016, RMD Open.

[8]  I. Koné-Paut.  Behçet’s disease in children, an overview , 2016, Pediatric Rheumatology.

[9]  N. Klein,et al.  Paediatric Behçet’s disease: a UK tertiary centre experience , 2016, Clinical Rheumatology.

[10]  S. Ozen,et al.  Consensus classification criteria for paediatric Behçet's disease from a prospective observational cohort: PEDBD , 2015, Annals of the rheumatic diseases.

[11]  A. Carta,et al.  Neuro-Behçet’s disease in childhood: A focus on the neuro-ophthalmological features , 2013, Orphanet Journal of Rare Diseases.

[12]  A. Ma,et al.  A20: linking a complex regulator of ubiquitylation to immunity and human disease , 2012, Nature Reviews Immunology.

[13]  S. Saip,et al.  Clinical characteristics of pediatric-onset neuro-Behçet disease , 2011, Neurology.

[14]  M. Kool,et al.  A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis , 2011, Nature Genetics.

[15]  L. Atmaca,et al.  Behçet Disease in Children , 2011, Ocular immunology and inflammation.

[16]  A. Waisman,et al.  A20 deficiency in B cells enhances B‐cell proliferation and results in the development of autoantibodies , 2011, European journal of immunology.

[17]  K. Amann,et al.  B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. , 2011, Blood.

[18]  M. Pasparakis,et al.  Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor–induced toxicity and experimental colitis , 2010, The Journal of experimental medicine.

[19]  J. Todd,et al.  Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus , 2009, Genes and Immunity.

[20]  M Bruinenberg,et al.  Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-κB signalling , 2009, Gut.

[21]  Pui-Yan Kwok,et al.  Genomewide Scan Reveals Association of Psoriasis with IL-23 and NF-κB Pathways , 2008, Nature Genetics.

[22]  M. Borlu,et al.  Demographic and clinical properties of juvenile-onset Behçet's disease: A controlled multicenter study. , 2008, Journal of the American Academy of Dermatology.

[23]  D. Strachan,et al.  Rheumatoid arthritis association at 6q23 , 2007, Nature Genetics.

[24]  S. Gabriel,et al.  Two independent alleles at 6q23 associated with risk of rheumatoid arthritis , 2007, Nature Genetics.

[25]  Simon C. Potter,et al.  Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.

[26]  S. Shoelson,et al.  Tag Polymorphisms at the A20 (TNFAIP3) Locus Are Associated With Lower Gene Expression and Increased Risk of Coronary Artery Disease in Type 2 Diabetes , 2007, Diabetes.

[27]  Somasekar Seshagiri,et al.  De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling , 2004, Nature.

[28]  I. Touitou,et al.  Paediatric Behçet's disease in France , 2002, Annals of the rheumatic diseases.

[29]  A. Ma,et al.  Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. , 2000, Science.

[30]  L. Harel,et al.  Childhood Behçet's disease: clinical features and comparison with adult-onset disease. , 1999, Rheumatology.

[31]  S. Ozen,et al.  Clinical features of Behçet's disease in children: an international collaborative study of 86 cases. , 1998, The Journal of pediatrics.

[32]  O. Ohara,et al.  A Japanese family case with juvenile onset Behçet's disease caused by TNFAIP3 mutation. , 2017, Allergology international : official journal of the Japanese Society of Allergology.

[33]  L. Catrysse,et al.  A20 in inflammation and autoimmunity. , 2014, Trends in immunology.

[34]  S. Ozen,et al.  Registries in rheumatological and musculoskeletal conditions. Paediatric Behçet's disease: an international cohort study of 110 patients. One-year follow-up data. , 2011, Rheumatology.